Loading asset research
Q3 2026 earnings · Nov 9
Immunovant Inc. Common Stock
IMVTNasdaq · USD · StocksQuote as of · Exchange session not verified$33.32
-2.00%
Today
IMVT
Loading 1D prices…
Market cap
$6.9B
Volume
2.4M
52w high
$45.4252w low
$15.56Company profile
Immunovant Inc. Common Stock
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Durham, NC, United States
Employees
315
Fiscal year end
0331
CIK
1764013
Session & valuation
Open$34.00
Previous close$34.00
Day high$34.22
Day low$33.17
30-day avg. volume1.4M
Outstanding shares206.6M
Diluted EPS-$2.77
Latest annual period
P/E (trailing)-12.03
P/E (forward)-12.11
Price / book9.34
Beta0.81
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CGONCG Oncology Inc. Common stock | $6B | $4M | -3985.15% | -$2.08 | -2.27% | Buy |
| SRRKScholar Rock Holding Corporation Common Stock | $5.9B | $0.00 | — | -$3.29 | +0.12% | Buy |
| PCVXVaxcyte Inc. Common Stock | $8.4B | $0.00 | — | -$5.63 | -1.12% | Buy |
| IBRXImmunityBio Inc. Common Stock | $8.9B | $113.3M | -310.27% | -$0.38 | -2.37% | Buy |
| CRSPCRISPR Therapeutics AG Common Shares | $5.2B | $3.5M | -16569.77% | -$6.47 | -2.64% | Buy |